CM Management LLC Increases Position in OS Therapies Inc (NYSE:OSTX)

CM Management LLC grew its holdings in OS Therapies Inc (NYSE:OSTX) by 120.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,044 shares of the company’s stock after purchasing an additional 60,044 shares during the quarter. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 as of its most recent SEC filing.

Separately, Virtu Financial LLC purchased a new position in OS Therapies during the third quarter worth approximately $28,000.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on OSTX. D. Boral Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a research note on Thursday, February 20th. Maxim Group raised their price objective on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, January 16th.

Insider Activity at OS Therapies

In other OS Therapies news, major shareholder Shalom Auerbach sold 16,720 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total value of $112,692.80. Following the sale, the insider now owns 2,531,211 shares of the company’s stock, valued at $17,060,362.14. The trade was a 0.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

OS Therapies Stock Down 4.8 %

Shares of OS Therapies stock opened at $1.60 on Friday. OS Therapies Inc has a 52 week low of $1.41 and a 52 week high of $7.00. The business’s fifty day simple moving average is $2.77 and its 200-day simple moving average is $3.00.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.